CCR researchers show selumetinib shrinks tumors in children with NF1

Findings from a phase 2 clinical trial show that the drug selumetinib improves outcomes for children with the genetic disorder neurofibromatosis type 1 (NF1). In the trial, selumetinib shrank the inoperable tumors that develop with NF1 called plexiform neurofibromas, and children experienced reduced pain, improved function, and better overall quality of life after receiving the treatment. This trial was led by Brigitte Widemann, M.D., Chief of the Pediatric Oncology Branch (POB), and Andrea M. Gross, M.D., Assistant Research Physician in POB, and the results were published March 18, 2020, in the New England Journal of Medicine. Read more...

CCR researchers show selumetinib shrinks tumors in children with NF1
Doug Lowy and John Schiller

The New York Times highlights the importance of physician-scientists

Sep 27, 2019

The New York Times recently posted an editorial highlighting the importance of physician-scientists in the medical field. The article cited several examples of discoveries made by physician-scientists that have changed the history of medicine, including the development of the HPV vaccine by Doug Lowy, M.D., Chief of the Laboratory of Cellular Oncology (LCO), and John Schiller, Ph.D., Deputy Chief of LCO. Read more...

cross-section of a cell nucleus

Advanced imaging technology reveals pulsed hormone release regulates gene transcription

Sep 19, 2019

Using advanced microscopic imaging technology, CCR investigators have correlated a pulsed pattern of hormone release with bursts of transcription, the process in which the genetic information encoded by DNA is written into RNA. They are the first researchers to observe this process at a gene-specific level. Read more...

Remi Adelaiye-Ogala with Nigerian flag

The Center for Cancer Research celebrates National Postdoc Appreciation Week

Sep 16, 2019

This week, we’re celebrating National Postdoc Appreciation Week. Our postdocs come from around the world to train at the Center for Cancer Research, and they are vital members of our cancer research community. Hear from some of our international postdocs on why they came here to train, and learn more about our training programs. Read more...

Karlyne Reilly

Karlyne Reilly discusses childhood cancer on BioMedCentral

Sep 16, 2019

Karlyne M. Reilly, Ph.D., Senior Associate Scientist in the Pediatric Oncology Branch, recently wrote a blog for BioMedCentral. In the blog, Dr. Reilly addresses both the difficulties and the importance of accessing and collecting data from childhood cancer clinical trials and initiatives, such as MyPART, to help improve childhood cancer research in the future.  Read more...

3D structure of a melanoma cell

Tumor composition of melanoma indicates potential responses to immunotherapy

Sep 13, 2019

The number of genetic mutations in a tumor is thought to influence how well melanoma may respond to immunotherapy, but new research in mice and supported by preliminary human data reveals that the diversity of mutations within a tumor may be a better indicator of response to therapy. Read more...

Dom and camp counselors

Neurofibromatosis type 1 patient attends Camp Fantastic for the first time

Sep 12, 2019

Thirteen-year-old Dom was diagnosed with neurofibromatosis type 1 at birth. Because of Dom’s diagnosis, he hasn’t always had the opportunity to do the things the average teenager does, but his first year at Camp Fantastic changed that. Camp Fantastic, an annual week-long camp for pediatric cancer patients and survivors, gave Dom the opportunity to try lots of new things and some familiar ones in a setting of support, safety and friendship. Read more...

NIH IRP Speaking of Science

Michael Gottesman and Ira Pastan featured in NIH Intramural Research Program podcast

Sep 12, 2019

Michael Gottesman, M.D., Chief of the Laboratory of Cell Biology, and Ira Pastan, M.D., Co-Chief of the Laboratory of Molecular Biology, were recently featured in the NIH IRP podcast Speaking of Science. In the podcast, Dr. Gottesman and Dr. Pastan discussed how their research and discoveries have helped effectively treat cancer in order to improve and save potentially millions of lives.  Read more...

Lori Wiener

Lori Wiener selected as NYU Alumni Changemaker

Sep 10, 2019

Lori Wiener, Ph.D., DCSW, LCSW-C, Senior Associate Scientist in the Pediatric Oncology Branch, has been selected as a 2019 NYU Alumni Changemaker. Changemakers are selected by the NYU Alumni Association Board for their ability to reduce suffering, bring hope to the marginalized and save lives.  Read more...

Chart on how CAR T-cell therapy works

FDA grants breakthrough therapy designation for new CAR T-cell therapy for B-cell acute lymphoblastic leukemia

Sep 10, 2019

In August 2019, the U.S. Food and Drug Administration granted breakthrough therapy designation to an experimental immunotherapy being developed in the Center for Cancer Research (CCR) for the treatment of B-cell acute lymphoblastic leukemia (ALL), a type of blood cancer. The designation will advance CCR’s development and testing of an immunotherapy for children and young adults whose B-cell ALL is resistant to CD19-targeted immunotherapies.  Read more...

Follicular lymphoma

Clinical trial evaluates dual drug therapy for untreated follicular lymphoma

Sep 5, 2019

Follicular lymphoma (FL) is a cancer of white blood cells (B cells) that help your body fight infections. Investigators are leading a clinical trial at the NIH Clinical Center to see if a combination therapy can slow the growth of FL in patients who have not received prior treatment.  Read more...

Pages